IL319505A - S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon - Google Patents
S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferonInfo
- Publication number
- IL319505A IL319505A IL319505A IL31950525A IL319505A IL 319505 A IL319505 A IL 319505A IL 319505 A IL319505 A IL 319505A IL 31950525 A IL31950525 A IL 31950525A IL 319505 A IL319505 A IL 319505A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- type
- receptor modulators
- mediated diseases
- ifn mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263375668P | 2022-09-14 | 2022-09-14 | |
| PCT/EP2023/074961 WO2024056631A1 (en) | 2022-09-14 | 2023-09-12 | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319505A true IL319505A (en) | 2025-05-01 |
Family
ID=88093165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319505A IL319505A (en) | 2022-09-14 | 2023-09-12 | S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4587005A1 (de) |
| JP (1) | JP2025531208A (de) |
| KR (1) | KR20250065853A (de) |
| CN (1) | CN119866215A (de) |
| AU (1) | AU2023339761A1 (de) |
| CA (1) | CA3266513A1 (de) |
| CL (1) | CL2025000741A1 (de) |
| IL (1) | IL319505A (de) |
| MX (1) | MX2025003112A (de) |
| TW (1) | TW202416967A (de) |
| WO (1) | WO2024056631A1 (de) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2767585C (en) | 2009-07-16 | 2017-09-26 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| CA2772921A1 (en) | 2009-09-03 | 2011-03-10 | Medimmune, Llc | Type 1 interferon diagnostic |
| EP2852575A1 (de) | 2012-05-22 | 2015-04-01 | Actelion Pharmaceuticals Ltd. | Verfahren zur herstellung von 2-cyclopentyl-6-methoxy-isonikotinsäure |
| PH12017502097B1 (en) | 2015-05-20 | 2023-05-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| JP2022512796A (ja) | 2018-10-26 | 2022-02-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｉ型インターフェロンシグネチャー及び使用方法 |
| TW202237647A (zh) | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
-
2023
- 2023-09-12 IL IL319505A patent/IL319505A/en unknown
- 2023-09-12 AU AU2023339761A patent/AU2023339761A1/en active Pending
- 2023-09-12 WO PCT/EP2023/074961 patent/WO2024056631A1/en not_active Ceased
- 2023-09-12 EP EP23772150.1A patent/EP4587005A1/de active Pending
- 2023-09-12 CA CA3266513A patent/CA3266513A1/en active Pending
- 2023-09-12 JP JP2025515759A patent/JP2025531208A/ja active Pending
- 2023-09-12 CN CN202380065852.6A patent/CN119866215A/zh active Pending
- 2023-09-12 KR KR1020257010901A patent/KR20250065853A/ko active Pending
- 2023-09-13 TW TW112134792A patent/TW202416967A/zh unknown
-
2025
- 2025-03-13 CL CL2025000741A patent/CL2025000741A1/es unknown
- 2025-03-14 MX MX2025003112A patent/MX2025003112A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025003112A (es) | 2025-05-02 |
| CA3266513A1 (en) | 2024-03-21 |
| JP2025531208A (ja) | 2025-09-19 |
| CN119866215A (zh) | 2025-04-22 |
| CL2025000741A1 (es) | 2025-05-23 |
| WO2024056631A1 (en) | 2024-03-21 |
| AU2023339761A1 (en) | 2025-03-20 |
| TW202416967A (zh) | 2024-05-01 |
| KR20250065853A (ko) | 2025-05-13 |
| EP4587005A1 (de) | 2025-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3755805A4 (de) | Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person | |
| IL285647A (en) | Material and system for the therapeutic treatment of joints | |
| EP3934646A4 (de) | Pharmazeutische zusammensetzungen zur behandlung von augenkrankheiten oder -leiden | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| EP3362096A4 (de) | Ophthalmische behandlungszusammensetzung und trägerstoff zur freisetzung von pharmazeutischen substanzen oder therapeutika | |
| CY1125113T1 (el) | Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας | |
| EP3960858A4 (de) | Small-rna-medikament zur vorbeugung und behandlung von entzündungsbedingten erkrankungen und kombination davon | |
| EP3856168A4 (de) | Zusammensetzung und verwendung zur behandlung von morbus parkinson und verwandten erkrankungen | |
| EP4058017A4 (de) | Arzneimittelformulierungen und verfahren zur behandlung von stoffwechselstörungen | |
| EP3479826A4 (de) | Verwendung von methyl-4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrat zur herstellung eines medikaments zur behandlung von psoriasis und vitiligo | |
| ZA202101688B (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| PT4031117T (pt) | Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos | |
| IL319505A (en) | S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| EP4232819A4 (de) | Verfahren zur beurteilung der therapeutischen aktivität von mitteln zur behandlung von immunerkrankungen | |
| IL326583A (en) | Stable GLP-1 analogs for the treatment of human diseases and disorders | |
| SMT202500307T1 (it) | Derivati di 1-metil-1h-pirazol-3-ile per l’uso nel trattamento di malattie neovascolari | |
| EP3549596A4 (de) | Verwendung von microcystinen zur herstellung von arzneimitteln zur prävention oder behandlung von organ- und gewebefibroseerkrankungen | |
| PT3937948T (pt) | Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares | |
| IL277041A (en) | Modulators of small conductance calcium activated k channels and pharmaceutical compositions for use in the treatment of lesional vestibular disorders | |
| EP3386516A4 (de) | Pharmazeutische formulierungen zur behandlung von hauterkrankungen sowie verfahren zur herstellung und verwendung davon | |
| LT4048229T (lt) | Farmacinė kompozicija, skirta panaudoti įvairių etiologijų cistito gydymui | |
| IL304606A (en) | Medicinal combinations of Rosuvastatin and Resmetiram for the treatment of liver disorders or lipid disorders | |
| CA3261529A1 (en) | Hydrogel composition intended for use in the treatment of joint disorders | |
| AU2021381054A9 (en) | Pharmaceutical compositions for use in the management and treatment of pain |